New Chronic Myelogenous Leukemia Guidelines for Patients Available from NCCN
NCCN has released the NCCN Patient Guidelines for Chronic Myelogenous Leukemia, available free of charge on NCCN.com. NCCN Patient Guidelines are a tool to help patients and their caregivers take a more active role in treatment decisions.
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®), with the support of the NCCN Foundation, recently announced the latest addition to the library of NCCN Guidelines for Patients™, the NCCN Patient Guidelines™ for Chronic Myelogenous Leukemia. This resource is a patient-friendly, easy-to-understand translation of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Chronic Myelogenous Leukemia (CML), which physicians use when determining appropriate cancer treatment. The NCCN Patient Guidelines aim to help patients with cancer and their loved ones discuss the best treatment options for them with their physicians.
More than 4,500 new cases of CML are diagnosed in the United States each year, with most cases occurring in adults. CML is one of four major types of leukemia and accounts for 15 percent of adult leukemias. It is a leukemia that grows slowly and causes too many white blood cells to form. People diagnosed with CML often have more than one treatment option, including, but not limited to, tyrosine kinase inhibitors, chemotherapy, or hematopoietic stem cell transplantation.
The NCCN Guidelines™ are developed by multidisciplinary panels of experts from NCCN Member Institutions and feature algorithms or decision trees that address every appropriate management option from initial work-up throughout the course of the disease. The NCCN Patient Guidelines translate these professional guidelines in a clear, step-by-step manner that patients can use as the basis for making decisions and discussing treatment options with their physicians.
The NCCN Patient Guidelines are available free of charge at NCCN.com, which, in addition, features informative articles for patients and caregivers. NCCN also offers six other NCCN Patient Guidelines including Breast, Non-Small Cell Lung, Ovarian and Prostate Cancers, and Melanoma and Multiple Myeloma. By the end of 2011, NCCN aims to have 10 new and updated NCCN Patient Guidelines added to the library, with the next NCCN Patient Guidelines for Malignant Pleural Mesothelioma scheduled for release in the summer of 2011.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- University of Wisconsin Carbone Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital